ENvue Medical, Inc. (FEED): Nasdaq/NYSE listing notice — NanoVibronix receives NASDAQ deficiency notice for minimum stockholders' equity

ENvue Medical, Inc.

Stockholders' equity of ~$2.2M as of March 31, 2023, is below NASDAQ's $2.5M minimum.
Company does not meet alternative compliance standards ($35M market value or $500K net income).
Must submit a plan to regain compliance by July 7, 2023; NASDAQ may grant up to 180-day extension.
Failure to regain compliance could lead to delisting of common stock from Nasdaq Capital Market.
Management intends to evaluate courses of action but provides no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 23, 2023, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (“NASDAQ”) indicating that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing Rule 5550(b)(1) for continued listing on The NASDAQ Capital Market because the Company’s stockholders’ equity of approximately $2.2 million as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, is below the required minimum of $2.5 million, and as of May 22, 2023, the Company does not meet t

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ENvue Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.